tbuckley/cabot-search huggingface dataset:
PATIENT EXPERIENCE WITH DIGITAL NAVIGATION DURING CARDIAC CATHETERIZATION: EARLY FINDINGS FROM ACC DIGITAL TRANSFORMATION NETWORK PIONEER COHORT
Authors: Annapoorna Subhash Kini, Usman Baber, Andriy Vengrenyuk, Melody Burgo, Farah Fasihuddin, Natalie Bishop, Sravya Kurra, Shashank Garg, Sarthak Kakkar, Shrawan Patel, Jeffrey Bander, Joseph Sweeny, Ashish Atreja
Journal: Journal of the American College of Cardiology (2020)
HEART FAILURE OUTCOMES IN A LARGE HIV POPULATION AT A SAFETY-NET ACADEMIC MEDICAL CENTER
Authors: Anjali B. Thakkar, Yifei Ma, Martha Michel, Jennifer Creasman, Nalini Colaco, Teresa Wang, Alexandra Teng, Smruti Rahalkar, Rebecca Scherzer, Priscilla Y. Hsue
Journal: Journal of the American College of Cardiology (2020)
Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial
Authors: Ian D Pavord, Mark Holliday, Helen K Reddel, Irene Braithwaite, Stefan Ebmeier, Robert J Hancox, Tim Harrison, Claire Houghton, Karen Oldfield, Alberto Papi, Mathew Williams, Mark Weatherall, Richard Beasley, Andrew Corin, Colin Helm, Bhuwan Poudel, Davitt Sheahan, Pamela Sheahan, Miriam Bennett, Caterina Chang, Hollie Ellis, Bob Hancox, Sandra Hopping, Christine Tuffery, James Michael Ramsahai, Jodie Simpson, Peter Wark, Maria Aliani, Maddalena Genco, Alberto Capozzolo, Mauro Carone, Elisa Maini, Jenny Mancin, Antonio Meriggi, Luca Perfetti, Francesca Cherubino, Antonio Spanevello, Dina Visca, Elisabetta Zampogna, Christina Baggott, Richard Beasley, Irene Braithwaite, Allie Eathorne, Stefan Ebmeier, James Fingleton, Jo Hardy, Mark Holliday, Claire Houghton, Karen Oldfield, Janine Pilcher, Donah Sabbagh, Alex Semprini, Mathew Williams, Tim Harrison, Karen Shaw, Summer Mackisack, Barney Montgomery, Karen Autridge, Joanna Joseph, Stella Moon, Dean Quinn, Dean Millar-Coote, Jim Reid, Federico Bellini, Martina Marchi, Luca Morandi, Marianna Padovani, Alberto Papi, Daniela Scalet, Katie Borg, Clare Connolly, Anna Gittins, Gareth Hynes, Helen Jeffers, Ian Pavord, Rahul Shrimanker, Gloria Foxley, Elyse Guevara-Rattray, Stephen Milne, Helen Reddel, Brett Toelle
Journal: The Lancet Respiratory Medicine (2020)
IMPACT OF PROPORTIONALITY OF SECONDARY MITRAL REGURGITATION ON OUTCOME AFTER TRANSCATHETER MITRAL VALVE REPAIR
Authors: Mathias Orban, Nicole Karam, Edith Lubos, Daniel Kalbacher, Simon Deseive, Lukas Stolz, Michael Neuss, Christian Butter, Fabien Praz, Mohammad Kassar, Aniela Petrescu, Roman Pfister, Christos Iliadis, Matthias Unterhuber, Philipp Lurz, Holger Thiele, Stephan Baldus, Ralph Stephan Von Bardeleben, Stefan Blankenberg, Steffen Massberg, Stephan Windecker, Joerg Hausleiter
Journal: Journal of the American College of Cardiology (2020)
COMPARISON OF SEVERITY IN NON-CULPRIT LESION BETWEEN STEMI AND NSTEMI
Authors: Takamasa Tanaka, Hirokuni Akahori, Takahiro Imanaka, Kojiro Miki, Toshio Kimura, Nagataka Yoshihara, Koji Yanaka, Masanori Asakura, Masaharu Ishihara
Journal: Journal of the American College of Cardiology (2020)
EFFECTS OF CANAGLIFLOZIN ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES BY BASELINE LOOP DIURETIC USE: DATA FROM THE CREDENCE TRIAL
Authors: Brendon Neuen, Kenneth Mahaffey, Christopher P. Cannon, Meg Jardine, Hiddo L. Heerspink, Bruce Neal, Clare Arnott, Zien Zhou, David M. Charytan, Rajiv Agarwal, George L. Bakris, Dick De Zeeuw, Tom Greene, Adeera Levin, David C. Wheeler, Norman Rosenthal, Hong Zhang, Bernard Zinman, Vlado Perkovic, Carol Pollock
Journal: Journal of the American College of Cardiology (2020)
EFFECT OF INCLISIRAN ON LDL-C REDUCTION ACROSS DIFFERENT BACKGROUND LIPID LOWERING TREATMENTS: ANALYSES FROM ORION-11
Authors: Kausik Kumar Ray, David Kallend, Lawrence Leiter, Frederick Raal, Wolfgang Koenig, Scott Wright, Peter Wijngaard, John J.P. Kastelein
Journal: Journal of the American College of Cardiology (2020)
Patient discussions of glucocorticoid-related side effects within an online health community forum
Authors: Arani Vivekanantham, Maksim Belousov, Lamiece Hassan, Goran Nenadic, William G Dixon
Journal: Annals of the Rheumatic Diseases (2020)

Increasing numbers of patients are sharing their health-related experiences online in forums, or on social media websites, such as Twitter and Facebook. This largely untapped source of data about patients’ experience of living with disease and its treatment may be useful in deriving drug safety information such as the occurrence, nature and impact of side effects.

Text mining techniques can transform free text into structured data amenable for analysis by automatically recognising mentions of various health conditions and their relationship to a particular medication. These techniques have been used to identify the occurrence of commonly discussed drug adverse events (AEs) from posts on Facebook and Twitter.1 2 They have also been used to identify discussions about benefits of drugs and how these benefits compared with the AEs, other treatment options, costs and complaints about the product.1

A recently published analysis of Twitter posts mentioning prednisolone or prednisone found insomnia and weight gain to be the most frequently discussed side effects.3 However, with the 140 (or more recently 280) character limit per tweet, any side effect information is limited to what can be included and discussed within this space.

HealthUnlocked (HU), Europe’s largest social media network for health that supports patients and healthcare providers, hosts over 700 communities (including the UK’s …
DISTAL VERSUS PROXIMAL TRANSRADIAL ACCESS IN CHRONIC TOTAL OCCLUSION PERCUTANEOUS CORONARY INTERVENTION: PROCEDURAL AND LONG-TERM OUTCOMES FROM THE PROGRESS CTO REGISTRY
Authors: Ilias Nikolakopoulos, Taral Patel, Abdul Sheikh, Wissam A. Jaber, Habib Samady, Jaikirshan Khatri, Robert W. Yeh, Hector Tamez Aguilar, Michael Koutouzis, Ioannis Tsiafoutis, Farouc Jaffer, Anthony Doing, Philip Dattilo, Barry F. Uretsky, Catalin Toma, Bassem Elbarouni, Mohamed Omer, Evangelia Vemmou, Iosif Xenogiannis, Bavana Rangan, Shuaib Abdullah, Subhash Banerjee, Santiago Garcia, M. Nicholas Burke, Emmanouil Brilakis
Journal: Journal of the American College of Cardiology (2020)
ANNULAR MEASUREMENTS IN BICUSPID AORTIC VALVE ARE LARGEST IN THE 20% SYSTOLIC PHASE: IMPLICATIONS FOR TAVR AND SAVR
Authors: Aman Gupta, Yan Yatsynovich, Mohamed Abdel-Aal Ahmed, Ishant Gupta, Ankush Lahoti, Sadik Panwar, Thammi Ramanan, Gerald Colern, Rose Hansen, Vijay Iyer
Journal: Journal of the American College of Cardiology (2020)
KAWASAKI DISEASE: ACUTE MYOCARDIAL INFARCTION OF ADULT-ONSET ASSOCIATED WITH A GIANT CORONARY ARTERY ANEURYSM
Authors: Yuji Nakayama, Junya Komatsu, Yuki Nishimura, Takako Fujita, Ryota Kida, Ryu-ichiro Imai, Yoko Nakaoka, Koji Nishida, Satoshi Yamamoto, Shu-ichi Seki, Sho-ichi Kubokawa, Masahiko Ikebuchi, Hiroyuki Irie, Kazuya Kawai, Naohisa Hamashige, Yoshinori L. Doi
Journal: Journal of the American College of Cardiology (2020)
T1 MAPPING AND EXTRACELLULAR VOLUME FOR THE EVALUATION OF MYOCARDIAL INTERSTITIAL MATRIX IN DIABETIC AND NON-DIABETIC PATIENTS WITH MULTIVESSEL CORONARY ARTERY DISEASE
Authors: Gustavo Andre Boeing Boros, Whady Hueb, Paulo Rezende, Cesar Nomura, Carlos Rochitte, Matheus Ribeiro, Anderson Roberto Dallazen, Fernando Faglioni Ribas, Thamara Morais, Eduardo Gomes Lima, Cibele Garzillo, Carlos Serrano, Jose Ramires, Roberto Kalil-Filho
Journal: Journal of the American College of Cardiology (2020)
A Phase II study of axitinib (AG-013736), a potent inhibitor of VEGFRs, in patients with advanced thyroid cancer
Authors: S. Kim, L. S. Rosen, E. E. Cohen, R. B. Cohen, A. Forastiere, A. M. Silva, K. F. Liau, R. L. Archer, P. Bycott, E. E. Vokes
Journal: Journal of Clinical Oncology (2006)

5529 Background: Elevated levels of VEGF have been found in thyroid tumor tissue compared to normal thyroid. Axitinib (AG-013736) is a novel small molecule inhibitor of the receptor tyrosine kinases with picomolar potency against VEGFR 1, 2 &amp; 3 and nanomolar potency against PDGFR-beta and KIT. A phase I study in solid tumors identified 5 mg BID as the therapeutic dose. A phase II study in renal cell cancer demonstrated significant efficacy with a response rate (RR) of 46% (Rini et al, ASCO 2005). This study examined the safety and efficacy of AG-013736 (AG) therapy for advanced thyroid cancer. Methods: 32 patients (pts) refractory to or not suitable candidates for Iodine ( 131 I) treatment were treated with AG 5 mg p.o. BID. Eligibility included measurable disease and ECOG performance status (PS) of 0 or 1. A Simon 2 stage minimax design was used (alpha = 0.1; beta = 0.1; null response rate (RR) = 5%; alternative RR = 20%). Results: The median age of 32 enrolled pts was 63 yrs (35–81), 20 (63%) were male, 12 (38%) were female. Histological subtypes include papillary: 19 pts (59%); follicular- 9 pts (28%), medullary- 2 pts (6%) and anaplastic-2 pts (6%). 25 pts (78%) had prior surgery, 19 pts (59%) had prior 131 I treatment, 15 pts (47%) had prior RT, 6 pts (19%) had prior Adriamycin. Best response as assessed by RECIST criteria is PR in 3 pts with 38%-48% regression and additional unconfirmed PRs in 3 pts. Two pts (follicular) have PR&gt;12 mos. Response assessments are ongoing. 12 patients have discontinued treatment: 6 pts (19%)-progression, 3 pts-adverse events (AEs) and 3 pts-other. Twenty pts (63%) remain on study. The range for time on study is (6, 469) days. Median progression free survival has not been reached. Preliminary safety data for 17 pts indicate most common treatment emergent AEs as fatigue (9 pts), nausea (5 pts), proteinuria ( 5pts ), dizziness (4pts). Gr. 3 AEs include proteinuria ( 2pts ), cough (1pt), dyspnea (1 pt), abdominal pain (1pt), dysphagia (1pt), fatigue (1pt), muscle weakness (1pt), anorexia (1pt). Gr. 2 hypertension was observed in 2 pts. Conclusions: AG-013736 has substantial anti-tumor activity in advanced thyroid cancer. Therapy is well tolerated with manageable toxicity. Further investigation in this setting is warranted. [Table: see text]
MACHINE LEARNING ALGORITHMS FOR PREDICTION OF PACEMAKER IMPLANTATION AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT
Authors: Takahiro Tsushima, Sadeer Al-Kindi, Fahd Nadeem, Joshua Clevenger, Guilherme Attizzani, Yakov Elgudin, Alan Markowitz, Marco Costa, Daniel I. Simon, Mauricio Arruda, Judith Mackall, Sergio Thal
Journal: Journal of the American College of Cardiology (2020)
Final results of a multicenter phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with metastatic gastric or gastroesophageal (GEJ) adenocarcinoma (NCI #6447)
Authors: M. A. Shah, R. K. Ramanathan, D. Ilson, J. Randazzo, G. K. Schwartz, A. Tse, D. D’Adamo, A. Levner, M. Capanu, D. P. Kelsen
Journal: Journal of Clinical Oncology (2006)

4020 Background: BEV improves survival in several solid tumors when combined with chemotherapy. CPT/CIS is active in gastric and GEJ cancers with a median time to progression(TTP) of 4.2 months, response rate(RR) of 30%, and median survival of ∼7 months (Pozzo Ann Onc 2004). Anti-angiogenic therapy for upper GI cancers is of concern due to a potential increased risk of perforation or GI bleed. We evaluated the efficacy and safety of the combination of CPT, CIS, and BEV in the treatment of gastric and GEJ cancers. Methods: 47 patients with previously untreated metastatic gastric or GEJ adenocarcinomas were treated with BEV 15mg/kg day 1, CPT 65mg/m 2 and CIS 30mg/m 2 days 1 and 8, every 21 days. The primary endpoint was TTP, with 90% power to demonstrate a 50% improvement in TTP (eg. from 5 to 7.5 months) over historical control. Safety, response, and survival were secondary endpoints. Results: Patient characteristics: median age 59 (range 25–75), KPS 90% (70%-100%), Male 34, Gastric/GEJ 27:20. With a median follow up of 9.0 months, median TTP is 9.9 months (95%CI: 6.5–11.8 months). In 33 patients with measurable disease, the RR (partial + complete) is 66.7% (95%CI: 51–83%). Median survival is 12.6 months (95%CI: 10.1–17.1 months). We observed no change in expected CPT/CIS related toxicity: eg. grade 3/4 neutropenia (29%), nausea/vomiting (10%), and diarrhea (13%). Possible BEV related toxicity includes 2 gastric perforations, 1 grade 3 peri-rectal fistula, 2 cardiac events(1 ischemia, 1 reduced ejection fraction), and 10 patients with grade 3/4 hypertension. Although the primary tumor was unresected in 35 patients, we observed only 1 patient with an upper GI bleed. Grade 3/4 thromboembolic events occurred in 25%. Conclusions: The combination of CPT/CIS/BEV is active in gastric and GEJ cancers. The toxicity profile is acceptable. The primary endpoint of improving TTP was exceeded by 100% with median TTP 9.9 months. Despite the majority of patients having their primary tumor unresected, GI bleeding was not significant. The thromboembolic and perforation rates with CPT/CIS are similar with or without BEV (Shah et al JCO 2005). Further development of BEV in gastric and GEJ cancers is clearly warranted. [Table: see text]
Ustekinumab for the treatment of moderate‐to‐severe plaque psoriasis in paediatric patients (≥ 6 to &lt; 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open‐label <scp>CADMUS</scp> Jr study
Authors: S. Philipp, A. Menter, A.F. Nikkels, K. Barber, I. Landells, L.F. Eichenfield, M. Song, B. Randazzo, S. Li, M.‐C. Hsu, Y. Zhu, S. DePrimo, A.S. Paller
Journal: British Journal of Dermatology (2020)

Limited options are available for treatment of paediatric psoriasis.To evaluate the efficacy and safety of ustekinumab in paediatric patients with psoriasis (≥ 6 to < 12 years of age).CADMUS Jr, a phase III, open-label, single-arm, multicentre study, evaluated ustekinumab in paediatric patients with moderate-to-severe plaque psoriasis. Patients received weight-based dosing of ustekinumab (< 60 kg: 0·75 mg kg-1 ; ≥ 60 to ≤ 100 kg: 45 mg; > 100 kg: 90 mg) administered by subcutaneous injection at weeks 0 and 4, then every 12 weeks through week 40. Study endpoints (all at week 12) included the proportions of patients achieving a Physician's Global Assessment score of cleared/minimal (PGA 0/1) and ≥ 75%/90% improvement in Psoriasis Area and Severity Index (PASI 75/90), and change in Children's Dermatology Life Quality Index (CDLQI). Serum ustekinumab concentrations, antidrug antibodies and cytokine levels were measured through week 52. Safety was evaluated through week 56.In total, 44 patients (median age 9·5 years) received at least one dose of ustekinumab. Three patients discontinued the study agent through week 40. At week 12, 77% of patients achieved PGA 0/1, 84% achieved PASI 75 and 64% achieved PASI 90 response. The mean change in CDLQI was -6·3. Trough serum ustekinumab concentrations reached steady state at weeks 28-52. The incidence of antidrug antibodies was 10% (n = 4). Mean serum concentrations of interleukin-17A/F and interleukin-22 were significantly reduced at weeks 12 and 52. Overall, 34 patients (77%) had at least one adverse event and three (7%) had a serious adverse event.Ustekinumab effectively treated moderate-to-severe psoriasis in paediatric patients, and no new safety concerns were identified. What is already known about this topic? Ustekinumab is approved for use in adolescents (≥ 12 to < 18 years of age) and adults (≥ 18 years) with moderate-to-severe psoriasis. What does this study add? Ustekinumab effectively treats moderate-to-severe psoriasis in paediatric patients (≥ 6 to < 12 years of age), with no new safety concerns. Linked Comment: Reich. Br J Dermatol 2020; 183:606-607.
Impact of asbestos exposure on survival and treatment of patients with malignant mesothelioma.
Authors: Patrick P Bourgouin, Normand Blais, Mustapha Tehfe, Marie Florescu
Journal: Journal of Clinical Oncology (2012)

e17507 Background: Malignant mesothelioma is a rare pleural cancer heavily correlated to asbestos exposure. However, the number of mesotheliomas without any known exposure to asbestos is surely increasing. The impact of asbestos exposure on patient survival and response to standard treatment is unknown. We retrospectively analyzed 49 consecutive patients diagnosed with malignant mesothelioma using an unselected SARDO database at Notre-Dame Hospital from 2006 to 2009. Methods: Patients were sorted into 2 groups based on reported asbestos exposure status, mostly on patient’s working exposure. Demographic and treatment data were collected and analyzed with Kaplan-Meier survival plots and log-rank tests. Results: The median survival was 22.6 months for the entire 49 patients, overall survival at 1 year 86.4% and at 2 years 47.3%. Median survival of exposed patients (n = 20) was 22.6 months and that of non-exposed patients (n = 29) was 59.5 months. However, survival was not significantly different between the 2 groups (p = 0.450), despite there was no treatment difference in between 2 cohorts. Most patients were men (n = 42) and women (n=7) generally belonged to the non-exposed group. 3 patients had surgical treatment (pleurectomy with either pneumonectomy or lobectomy), but their survival was not statistically superior (p = 0.091) despite a clear trend. Patients younger than 65 years did not have better survival. Conclusions: Although asbestos exposure clearly increases the risk of mesothelioma, it does not seem to have an impact on the overall survival of patients with malignant mesothelioma neither on the efficiency of their treatment. However, a reliable serum biomarker of asbestos exposure would probably be necessary to make sure patients with no working exposure have really no exposure in other circumstances to asbestos.
PRECLINICAL CARDIAC DISEASE IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS WITH NO PRIOR CARDIAC HISTORY
Authors: Jeirym Miranda Tejada, Alaa M. Omar, Alvaro Garcia-Arenas, Oscar Milian, Opeoluwa Dehinbo, Murli Udharam Purswani, Jonathan N. Bella
Journal: Journal of the American College of Cardiology (2020)
Aneuploidy and neoplasia: Case of recurrent polysomy occurring at different times.
Authors: Giridhar U. Adiga, K H Ramesh, Tommy R Tong, Tomasz Jodlowski
Journal: Journal of Clinical Oncology (2013)

e22196 Background: Recurring polysomies in diverse tumors at different times may suggest common neoplastic mechanisms. Following case demonstrates similar polysomies in breast, endometrial and cholangiocarcinoma arising at different times. Methods: A 79-year-old African American female was diagnosed poorly differentiated cholangiocarcinoma. Tumor markers (CEA, AFP, CA19-9) were normal. FISH analysis with D3Z1 (centromere 3), D7Z1 (centromere 7), CDKN2A (9p21) and D17Z1 (centromere 17) DNA probes (Abbott Molecular, IL. USA) revealed polysomy of chromosomes 3, 7, 9 and 17. Oncology history includes tumors noted in the table. Medical history includes aortic aneurysm, hypertension, IPF, obesity, CKD, DJD, cholecystectomy and adjuvant tamoxifen. She was never pregnant, non smoker non alcoholic and no prior chemical exposures. Her maternal aunt had unclear pelvic cancer at 70. Her niece had duodenal cancer in 40s. Possible common initiating neoplastic mechanism or predisposition was speculated in view of multiple tumors. Archived specimens of previous tumors were tested using the same FISH probe set. Results: Similar pattern of aneuploidy was noted in cholandiocarcinoma, DCIS and endometrial polyp specimen and no such abnormalities in parathyroid adenoma and in normal tissue. Conclusions: Occurrences of similar polysomy in tumors originating from diverse tissues at different times but not in normal tissue suggest common predisposition and/or similar, nonrandom, neoplastic molecular events. Uncommon and previously not described polysomy pattern was noted in DCIS and in endometrial polyp. [Table: see text]
Impact of concomitant use of anti-acid agents on efficacy of gefitinib in EGFR-mutant non-small-cell lung cancer (NSCLC).
Authors: Kenichi Chikamori, Keisuke Aoe, Tadashi Maeda, Daizo Kishino, Keiji Oishi, Katsuyuki Hotta, Tsuneo Matsumoto, Hiroshi Ueoka
Journal: Journal of Clinical Oncology (2013)

e19008 Background: Gefitinib, an EGFR-tyrosine kinase inhibitor, is an essential agent for EGFR-mutant NSCLC. The preclinical studies revealed its reduced area under the curve (AUC) by elevation of pH in GI tract, potentially leading to alteration in the absorption of gefitinib. It, however, has been controversial as to whether and how simultaneous use of anti-acid agents, commonly used in clinical practices, could alter the sensitivity of gefitinib, especially in EGFR-mutant NSCLC. Thus, we conducted a retrospective cohort study to clarify this issue. Methods: We evaluated progression-free survival (PFS) and overall survival (OS) from the medical charts of chemotherapy-naïve patients with EGFR-mutant NSCLC treated with gefitinib monotherapy in our institution. We also identified history of concomitant use of anti-acid agents (proton pomp inhibitors and histamine type 2 receptor blockers) at the time of initiation of gefitinib therapy and assessed its impact on the efficacy of gefitinib using Cox’s proportional hazard model. Results: Between 2006 and 2012, consecutive 83 patients received gefitinib therapy, of whom 29 (34.9%) used anti-acid agents simultaneously. Baseline clinical characteristics between the two groups (use and non-use of anti-acid agents) were well balanced except performance status (PS) of 0: 17.2% vs. 37.0% respectively. Neither PFS nor OS were influenced by concomitant use of anti-acid agents in univariate analysis (hazard ratio: 1.12; 95% confidence interval: 0.66-1.92 and 1.67; 0.86-3.44, respectively). Multivariate analysis also showed no significant effect of anti-acid agent use on PFS and OS (1.18; 0.67-2.06 and 1.66; 0.81-3.38, respectively), whilst poor PS affected OS (2.03; 1.27-3.26). Additionally, no difference in the impact of use of anti-acid agents on the gefitinib sensitivity was observed when stratified by the type of EGFR mutations. Conclusions: Concomitant use of anti-acid agents does not seem to affect efficacy of gefitinib in EGFR-mutant NSCLC. It is unlikely that physicians need to keep in mind the drug interaction of gefitinib and anti-acid agents in daily clinical practices, although further extensive cohort studies are warranted.
OUTCOMES FOLLOWING ENDOVASCULAR THERAPY IN TYPE B ACUTE AORTIC DISSECTION STRATIFIED BY RISK LEVEL
Authors: Regan Fleisher, Thomas G. Gleason, G. Chad Hughes, Toru Suzuki, Hans-Henning Eckstein, Joseph S. Coselli, Ali Khoynezhad, Clayton Kaiser, Daniel G. Montgomery, Jessica P. Simons, Gilbert R. Upchurch, Marco Di Eusanio, Christoph Nienaber, Himanshu J. Patel, Patrick T. O’Gara, Thoralf M. Sundt, Kim Eagle
Journal: Journal of the American College of Cardiology (2020)
Ageing and longevity in UK need more funding and research, peers are told
Authors: Adrian O’Dowd
Journal: BMJ (2020)

Ageing and life expectancy are vital issues that need more attention and investment for research, experts have told peers on the House of Lords science and technology committee.

Witnesses from research councils, drug companies, clinicians, and investors highlighted the importance of research into this area in an evidence session on 10 March for the committee’s inquiry into ageing, science, technology, and healthy living.

The committee asked the witnesses whether the UK was investing enough in research on the processes of ageing, particularly healthy ageing, as well as new drugs that could prevent older people from getting diseases.

Fiona Watt, executive chair of the Medical Research Council, giving evidence, said, “The proportion of …
ACUTE RATE CONTROL OF ATRIAL FIBRILLATION WITH RAPID VENTRICULAR RESPONSE USING INTRAVENOUS CALCIUM CHANNEL BLOCKERS OR INTRAVENOUS BETA BLOCKERS LEADS TO CARDIOGENIC SHOCK IN PATIENTS WITH UNDERLYING SYSTOLIC DYSFUNCTION
Authors: Eric Sun, Karim Diab, Christopher Leyton, Daryl Nnani, Sandhya Murthy, Chavez Patricia, Omar Saeed, Sasa Vukelic, Snehal Patel, Jooyoung Shin, Mario Garcia, Ulrich Jorde, Daniel Sims
Journal: Journal of the American College of Cardiology (2020)